VivoSeq
Oncology

T Acute Lymphoblastic Leukemia

14

Pipeline Programs↗

0

Active Trials↗

9

Companies Involved↗

T Acute Lymphoblastic Leukemia is an emerging landscape with 14 programs across 9 companies. The most active players are Eastern Cooperative Oncology Group, Dutch Childhood Oncology Group, Teva. 14 programs are in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

41/100

Pipeline Velocity

0/100

Mech. Concentration

22/100

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

E

Eastern Cooperative Oncology Group

3 programs

Phase 3D

Dutch Childhood Oncology Group

1 program

Phase 3Teva logo

Teva

1 program

Phase 3G

Gynecologic Oncology Group

1 program

Phase 3S

Stason

1 program

Phase 3Alnylam Pharmaceuticals logo

Alnylam Pharmaceuticals

1 program

Phase 3

Pipeline

Programs by Phase

Analysis

Modality Breakdown

86%

Small molecule

12 of 14 classified programs — the dominant modality here.

14%ALL OTHERSProtein / enzyme214%

Small molecule leads; the ring shows all 14 classified programs, each share of the total. Modality classified for 100% of 14 pipeline programs.

Analysis

Trial Status

1

clinical trials

Completed1 · 100%

Clinical Trials

Trial Activity

Intensified Methotrexate, Nelarabine (Compound 506U78) and Augmented BFM Therapy for Children and Young Adults With Newly Diagnosed T-cell Acute Lymphoblastic Leukemia (ALL) or T-cell Lymphoblastic Lymphoma
Completed·National Cancer Institute (NCI)·Phase 3·NCT00408005·1,895 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)